Raymond Monteleone serves as Director of the Company. Mr. Monteleone currently serves as the chairman and president of Paladin Global Partners, LLC since 2007; a board member and vice president of Dannelly, Monteleone & Associates, LLC since 2010; sits on the board of Chenmoore Engineering Inc. since 2015; is a managing member at Diner Investment Partners, LLC since 2016 and Uyona Management, LLC since 2013; a managing member and the chief financial officer at HBRE, LLC since 2013 and Horne Management, LLC since 2011; and the president at Monteleone & Associates Consulting, Inc. since 2005. Mr. Monteleone received a college degree from the New York Institute of Technology and an MBA degree from Florida Atlantic University. Mr. Monteleone is presently the interim CFO of LVI Intermediate Holdings, Inc. A former partner with Arthur Young (now EY), Ray Monteleone joined H-CYTE after working closely with several large and small companies serving as board member and/or advisor, specializing in strategic planning, health care, tax and financial planning and corporate management. Mr. Monteleone previously held officer positions with Sensormatic Electronics Corporation, a billion-dollar company listed in the New York Stock Exchange and was a member of the Board of Directors of Rexall Sundown, Inc., a large public entity. He also previously served as an officer working closely with the Board of Directors of Laser Spine Institute (“LSI”) and worked as deputy commissioner, chief operating officer, and chief financial officer with the Florida Department of Education. He attended an exclusive Arthur Young Harvard Business School program and earned his MBA from Florida Atlantic University. Considered an expert in financial analysis and business management, Monteleone is regularly featured as a lecturer at various universities and professional associations.
Raymond Monteleone is 72, he's been the Director of H-CYTE since 2019. There are no older and 8 younger executives at H-CYTE.
Raymond's mailing address filed with the SEC is 201 E KENNEDY BLVD,, SUITE 700, TAMPA, FL, 33606.
Over the last 6 years, insiders at H-CYTE have traded over $0 worth of H-CYTE stock and bought 60,000 units worth $8,050 . The most active insiders traders include Todd Rfwhc Holdings, Llc Wa..., J Rex Iiifwhc Holdings, Llc... y Michael Yurkowsky. On average, H-CYTE executives and independent directors trade stock every 286 days with the average trade being worth of $10,590,590. The most recent stock trade was executed by J Rex Iiifwhc Holdings, Llc... on 23 February 2022, trading 693,477 units of HCYT stock currently worth $6,935.
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute biologics for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
H-CYTE executives and other stock owners filed with the SEC include: